SK15082003A3 - Spôsob prípravy amorfného cilastatínu sodného - Google Patents

Spôsob prípravy amorfného cilastatínu sodného Download PDF

Info

Publication number: SK15082003A3
Authority: SK; Slovakia
Prior art keywords: solvent; cilastatin; sodium; cilastatin sodium; solution
Prior art date: 2001-05-18

Application number

SK1508-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Yatendra Kumar

Om Dutt Tyagi

Amit Rohtagi

Original Assignee

Ranbaxy Laboratories Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-18

Filing date

2002-05-17

Publication date

2004-06-08

2002-05-17 Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited

2004-06-08 Publication of SK15082003A3 publication Critical patent/SK15082003A3/sk

Links

229960003716 cilastatin sodium Drugs 0.000 title claims abstract description 47
JSAKRLDIZOGQTN-UHFFFAOYSA-M 4-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-1-sulfonate Chemical compound OC1=C(C2=CC=CC=C2C=C1)N=NC1=CC=C(C2=CC=CC=C12)S(=O)(=O)[O-] JSAKRLDIZOGQTN-UHFFFAOYSA-M 0.000 title claims abstract description 46
238000000034 method Methods 0.000 title claims abstract description 27
238000002360 preparation method Methods 0.000 title claims abstract description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
239000002904 solvent Substances 0.000 claims description 27
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
239000012296 anti-solvent Substances 0.000 claims description 12
229960004912 cilastatin Drugs 0.000 claims description 11
DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
239000003960 organic solvent Substances 0.000 claims description 9
239000008240 homogeneous mixture Substances 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
238000001556 precipitation Methods 0.000 claims description 3
239000011541 reaction mixture Substances 0.000 claims description 2
229910004354 OF 20 W Inorganic materials 0.000 claims 1
238000001914 filtration Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000004108 freeze drying Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 4
239000000463 material Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
-1 2,2-dimethylcyclopropyl Chemical group 0.000 description 1
GJCSXQWYMSOSDU-UHFFFAOYSA-N 2-aminohept-2-enoic acid Chemical compound CCCCC=C(N)C(O)=O GJCSXQWYMSOSDU-UHFFFAOYSA-N 0.000 description 1
YURNCBVQZBJDAJ-UHFFFAOYSA-N 2-heptenoic acid Chemical compound CCCCC=CC(O)=O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 1
206010005940 Bone and joint infections Diseases 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
208000002633 Febrile Neutropenia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000036209 Intraabdominal Infections Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000000774 cystein-S-yl group Chemical group 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
229960002182 imipenem Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000000967 suction filtration Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/02—Monohydroxylic acyclic alcohols
- C07C31/04—Methanol
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/26—Separation; Purification; Stabilisation; Use of additives
- C07C319/28—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Cephalosporin Compounds (AREA)

SK1508-2003A 2001-05-18 2002-05-17 Spôsob prípravy amorfného cilastatínu sodného SK15082003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN593DE2001		2001-05-18
PCT/IB2002/001696 WO2002094742A1 (en)	2001-05-18	2002-05-17	Process for the preparation of amorphous cilastatin sodium

Publications (1)

Publication Number	Publication Date
SK15082003A3 true SK15082003A3 (sk)	2004-06-08

Family

ID=11097060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1508-2003A SK15082003A3 (sk)	2001-05-18	2002-05-17	Spôsob prípravy amorfného cilastatínu sodného

Country Status (24)

Country	Link
US (1)	US20040152780A1 (et)
EP (1)	EP1395530A4 (et)
JP (1)	JP2004526805A (et)
KR (1)	KR20040044409A (et)
CN (1)	CN1522235A (et)
AP (2)	AP1511A (et)
AR (1)	AR036017A1 (et)
BG (1)	BG108447A (et)
BR (1)	BR0209843A (et)
CA (1)	CA2447788A1 (et)
CZ (1)	CZ20033352A3 (et)
EA (1)	EA005947B1 (et)
EE (1)	EE200300567A (et)
HR (1)	HRP20031052A2 (et)
HU (1)	HUP0400825A2 (et)
IL (1)	IL158945A0 (et)
MX (1)	MXPA03010547A (et)
NO (1)	NO20035138D0 (et)
NZ (1)	NZ529625A (et)
OA (1)	OA12607A (et)
PL (1)	PL367937A1 (et)
SK (1)	SK15082003A3 (et)
WO (1)	WO2002094742A1 (et)
ZA (1)	ZA200309287B (et)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007054771A2 (en) *	2005-11-09	2007-05-18	Orchid Chemicals & Pharmaceuticals Limited	An improved process for the preparation of cilastatin and sodium salt
US20120253066A1 (en) *	2010-01-01	2012-10-04	Orchid Chemicals & Pharmaceuticals Limited	Process for the preparation of cilastatin sodium
CN102675175B (zh) *	2011-03-08	2014-02-19	深圳市海滨制药有限公司	一种西司他丁的分离纯化方法
US11324804B2 (en)	2016-11-18	2022-05-10	Sepsia Therapeutics, S.L.	Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5147868A (en) *	1978-07-24	1992-09-15	Merck & Co., Inc.	Thienamycin renal peptidase inhibitors
US4292436A (en) *	1980-06-25	1981-09-29	Merck & Co., Inc.	Process for the preparation of N-protected N-formimidoyl 2-aminoethanethiol
DE69106897T2 (de) *	1990-02-08	1995-05-24	Sumitomo Chemical Co	Verfahren zur Herstellung von Haloketosäureabkömmlingen.
US5166417A (en) *	1990-09-04	1992-11-24	Lonza Ltd.	Process for resolution of racemates of 2,2-dimethylcyclopropanecarboxylic acid
CA2056840A1 (en) *	1990-12-17	1992-06-18	Thomas Meul	Process for the production of dimethylcyclopropanecarboxylic acid
EP0524604B1 (de) *	1991-07-26	1998-10-14	Lonza A.G.	Gentechnologisches Verfahren zur Herstellung von S-(+)-2,2-Dimethylcyclopropancarboxamid mittels Mikroorganismen
US5245069A (en) *	1992-10-27	1993-09-14	Merck & Co., Inc.	Process for the preparation of bis(aryl)-phosphorohalidates
IN191798B (et) *	2000-11-03	2004-01-03	Ranbaxy Lab Ltd

2002
- 2002-05-17 CN CNA028131096A patent/CN1522235A/zh active Pending
- 2002-05-17 EP EP02727916A patent/EP1395530A4/en not_active Withdrawn
- 2002-05-17 BR BR0209843-1A patent/BR0209843A/pt not_active IP Right Cessation
- 2002-05-17 MX MXPA03010547A patent/MXPA03010547A/es not_active Application Discontinuation
- 2002-05-17 PL PL02367937A patent/PL367937A1/xx not_active Application Discontinuation
- 2002-05-17 HR HR20031052A patent/HRP20031052A2/xx not_active Application Discontinuation
- 2002-05-17 US US10/478,081 patent/US20040152780A1/en not_active Abandoned
- 2002-05-17 OA OA1200300301A patent/OA12607A/en unknown
- 2002-05-17 CZ CZ20033352A patent/CZ20033352A3/cs unknown
- 2002-05-17 CA CA002447788A patent/CA2447788A1/en not_active Abandoned
- 2002-05-17 JP JP2002591417A patent/JP2004526805A/ja not_active Withdrawn
- 2002-05-17 IL IL15894502A patent/IL158945A0/xx unknown
- 2002-05-17 KR KR10-2003-7015042A patent/KR20040044409A/ko not_active Withdrawn
- 2002-05-17 EA EA200301225A patent/EA005947B1/ru not_active IP Right Cessation
- 2002-05-17 HU HU0400825A patent/HUP0400825A2/hu unknown
- 2002-05-17 WO PCT/IB2002/001696 patent/WO2002094742A1/en not_active Ceased
- 2002-05-17 SK SK1508-2003A patent/SK15082003A3/sk unknown
- 2002-05-17 AP APAP/P/2003/002913A patent/AP1511A/en active
- 2002-05-17 AP APAP/P/2003/002912A patent/AP2003002912A0/en unknown
- 2002-05-17 NZ NZ529625A patent/NZ529625A/en unknown
- 2002-05-17 EE EEP200300567A patent/EE200300567A/et unknown
- 2002-05-20 AR ARP020101853A patent/AR036017A1/es not_active Application Discontinuation
2003
- 2003-11-18 NO NO20035138A patent/NO20035138D0/no not_active Application Discontinuation
- 2003-11-28 ZA ZA200309287A patent/ZA200309287B/en unknown
- 2003-12-12 BG BG108447A patent/BG108447A/xx unknown

Also Published As

Publication number	Publication date
KR20040044409A (ko)	2004-05-28
AR036017A1 (es)	2004-08-04
HUP0400825A2 (hu)	2004-08-30
AP1511A (en)	2005-12-20
BG108447A (en)	2005-03-31
US20040152780A1 (en)	2004-08-05
HRP20031052A2 (en)	2004-06-30
IL158945A0 (en)	2004-05-12
CA2447788A1 (en)	2002-11-28
NZ529625A (en)	2006-02-24
ZA200309287B (en)	2004-07-22
AP2003002913A0 (en)	2003-12-31
EP1395530A1 (en)	2004-03-10
MXPA03010547A (es)	2004-05-27
OA12607A (en)	2006-06-08
WO2002094742A1 (en)	2002-11-28
BR0209843A (pt)	2004-08-24
JP2004526805A (ja)	2004-09-02
PL367937A1 (en)	2005-03-07
CZ20033352A3 (en)	2004-06-16
EA200301225A1 (ru)	2004-06-24
EE200300567A (et)	2004-04-15
CN1522235A (zh)	2004-08-18
AP2003002912A0 (en)	2002-05-17
EA005947B1 (ru)	2005-08-25
NO20035138D0 (no)	2003-11-18
EP1395530A4 (en)	2006-01-18

Publication	Publication Date	Title
CZ302082B6 (cs)	2010-09-29	Prostredek zahrnující krystalograficky stabilní amorfní cefalosporin a zpusob jeho výroby
JP4338401B2 (ja)	2009-10-07	４−フェニル酪酸の合成
CA1121343A (fr)	1982-04-06	Procede de preparation d'une forme cristalline du sel de sodium d'un derive oximine de l'acide 7-amino thiazolyl acetamido cephalosporanique
CA1186682A (en)	1985-05-07	Crystalline salts of cefodizim and a process for their preparation
FI75571B (fi)	1988-03-31	Framstaellningsfoerfarande foer synnerligen kristalliniskt natriumcefoperazon.
SK15082003A3 (sk)	2004-06-08	Spôsob prípravy amorfného cilastatínu sodného
US7511135B2 (en)	2009-03-31	Method for manufacture of ceftiofur
CN103087080B (zh)	2016-08-31	一种盐酸头孢卡品酯的制备方法及其合成中间体
US11274164B2 (en)	2022-03-15	Method for the preparation of sulfobutylether beta cyclodextrin sodium
JPH0240676B2 (et)	1990-09-12
AU2002258073A1 (en)	2002-12-03	Process for the preparation of amorphous cilastatin sodium
CN103570618A (zh)	2014-02-12	一种孟鲁司特钠盐的制备方法
JPS5844082B2 (ja)	1983-09-30	ヘパリンの製法
JPS61145187A (ja)	1986-07-02	セフアロスポリン類
CN110678075B (zh)	2021-09-07	吡唑胺反应结晶
US6040445A (en)	2000-03-21	Acyclovir dihydrate sodium salt and the preparation thereof
JPH0157115B2 (et)	1989-12-04
JP2695035B2 (ja)	1997-12-24	２―（メチルチオ）バルビツル酸の製造方法
FI61517C (fi)	1982-08-10	Foerfarande foer framstaellning av 6-(d-(-)-alfa-amino-alfa-(p-hydroxifenylacetamido))penicillansyra
DK158673B (da)	1990-07-02	Analogifremgangsmaade til fremstilling af cephalosporinforbindelser.
JPS6097994A (ja)	1985-05-31	イソエフロトマイシン
JPH0158190B2 (et)	1989-12-11
JP2004514713A (ja)	2004-05-20	フェニレン−ビス−ベンゾイミダゾール−テトラスルホン酸二ナトリウム塩の製造方法
JPH04136001A (ja)	1992-05-11	β―シクロデキストリン・スルホンアミド誘導体のポリ硫酸エステル及びその製法
JPH04198184A (ja)	1992-07-17	３―置換チオメチルセフェムカルボン酸類またはその塩類の製造方法

Legal Events

Date	Code	Title	Description
2010-08-09	FB9A	Suspension of patent application procedure